Erratum to Animal models of brain maldevelopment induced by cycad plant genotoxins [Birth Defects Res C, 99 (2013) 247-255, 10.1002/bdrc.21052];Animal models of brain maldevelopment induced by cycad plant genotoxins

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 99, Issue 4, 2013, Pages 247-255

  Kisby, Glen E ^a   Moore, Holly ^b   Spencer, Peter S ^c  

^a Western University of Health Sciences   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Alkyladenine DNA glycosylase; Amyotrophic lateral sclerosis parkinsonism dementia complex; Cycasin; Methylazoxymethanol

Indexed keywords

AGLYCONE; AMINO ACID; AZOXYGLYCOSIDE; GENOTOXIN; GLYCOSIDE; HISTONE; HYDRAZINE DERIVATIVE; LYSINE; METHYLAZOXYMETHANOL; METHYLAZOXYMETHANOL GLUCOSIDE; METHYLAZOXYMETHANOL PRIMEVEROSIDE; NITROSAMINE; NITROSOUREA; PLANT TOXIN; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATAXIA; BRAIN; BRAIN DEVELOPMENT; BRAIN DISEASE; BRAIN MALDEVELOPMENT; CHEMISTRY; CYCADOPHYTA; DEGENERATIVE DISEASE; DEMENTIA; DNA DAMAGE; DNA REPAIR; EPILEPSY; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; GENE; HISTONE METHYLATION; HUMAN; INGESTION; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PLANT PRODUCT; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALIA; CYCADOPSIDA; MUS;

ALKYLADENINE DNA GLYCOSYLASE; AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM-DEMENTIA COMPLEX; CYCASIN; METHYLAZOXYMETHANOL; O6-METHYLGUANINE METHYLTRANSFERASE;

AMINO ACIDS, DIAMINO; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN; CYCAS; DISEASE MODELS, ANIMAL; DNA DAMAGE; HUMANS; MUTAGENS; NEUROTOXINS;

EID: 84890357527     PISSN: 1542975X     EISSN: 15429768     Source Type: Journal    
DOI: 10.1002/bdrc.21055     Document Type: Erratum

References (90)

1. Akbarian S. 2009. The molecular pathology of schizophrenia-focus on histone and DNA modifications. Brain Res Bull 83:103-107.
2. Arai JA, Feig LA. 2011. Long-lasting and transgenerational effects of an environmental enrichment on memory formation. Brain Res Bull 85:30-35.
3. Balduini W, Cimino M, Lombardelli G, et al. 1986. Microencephalic rats as a model for cognitive disorders. Clin Neuropharmacol 9:S8-S18.
4. Bassanini S, Hallene K, Battaglia G, et al. 2007. Early cerebrovascular and parenchymal events following prenatal exposure to the putative neurotoxin methylazoxymethanol. Neurobiol Dis 26:481-495.
5. Beaton JM. 1977. Dangerous Harvest: investigations in the late prehistoric occupation of southeast central Queeensland. PhD. thesis. Australian National University, Canberra.
6. 6-methylguanine-DNA methyltransferase deficiency in developing brain: implications for brain tumorigenesis. DNA Repair (Amst) 6:1127-1133.
7. Borenstein AR, Mortimer JA, Schofield E, et al. 2007. Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology 68:1764-1771.
8. Bugni JM, Meira LB, Samson LD. 2009. Alkylation-induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins. Oncogene 28:734-741.
9. Calcagnotto ME, Baraban SC. 2005. Prolonged NMDA-mediated responses, altered ifenprodil sensitivity, and epileptiform-like events in the malformed hippocampus of methylazoxymethanol exposed rats. J Neurophysiol 94:153-162.
10. Cattabeni F, Di Luca M. 1997. Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Physiol Rev 77:199-215.
11. Chen KM, Brody JA, Kurland LT. 1968. Patterns of neurologic diseases on Guam. Arch Neurol 19:573-578.
12. Chin CL, Curzon P, Schwartz AJ, et al. 2011. Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia. Synapse 65:393-403.
13. Chiu AS, Gehringer MM, Welch JH, Neilan BA. 2011. Does α-amino-β-methylaminopropionic acid (BMAA) play a role in neurodegeneration?. Int J Environ Res Public Health 8:3728-3746.
14. Close KCA, Gelegel N. 1975. Medicinal plants of the Maprik Area. Papua New Guinea Med J 18:153.
15. Colacitti C, Sancini G, DeBiasi S, et al. 1999. Prenatal methylazoxymethanol treatment in rats produces brain abnormalities with morphological similarities to human developmental brain dysgeneses. J Neuropathol Exp Neurol 58:92-106.
16. Dastur DK, Palekar RS. 1974. The experimental pathology of cycad toxicity with special reference to oncogenic effects. Indian J Cancer 2:33-49.
17. Fatemi SH, Folsom TD. 2009. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 35:528-548.
18. Ferguson SA. 1996. Neuroanatomical and functional alterations resulting from early postanatal cerebellar insults in rodents. Pharmacol Biochem Behav 55:663-671.
19. Ferguson SA, Paule MG, Holson RR. 1996. Functional effects of methylzoxymethanol-induced cerebellar hypoplasia in rats. Neurotoxicol Teratol 18:529-537.
20. Flagstad P, Mork A, Glenthoj BY, et al. 2004. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology 29:2052-2064.
21. Friedberg EC, Meira LB. 2004. Database of mouse strains carrying targeted mutations in genes affecting biological responses to DNA damage (Version 6). DNA Repair (Amst) 3:1617-1638.
22. Germano IM, Sperber EF. 1998. Transplacentally induced neuronal migration disorders: an animal model for the study of the epilepsies. J Neurosci Res 51:473-488.
23. Guo N, Yoshizaki K, Kimura R, et al. 2013. A sensitive period for GABAergic interneurons in the dentate gyrus in modulating sensorimotor gating. J Neurosci 33:6691-6704.
24. Harrington EP, Moddel G, Najm IM, Baraban SC. 2007. Altered glutamate receptor: transporter expression and spontaneous seizures in rats exposed to methylazoxymethanol in utero. Epilepsia 48:158-168.
25. Hatten ME. 1999. Central nervous system neuronal migration. Annu Rev Neurosci 22:511-539.
26. + /glucose cotransporter. Biochim Biophys Acta 1193:151-154.
27. Hirono I, Kachi H, Kato T. 1970. A survey of acute toxicity of cycads and mortality rate from cancer in the Miyako Islands, Okinawa. Acta Pathol Jpn 20:327-337.
28. Hoffman JR, Boyne LJ, Levitt P, Fischer I. 1996. Short exposure of methylazoxymethanol causes a long-term inhibition of axonal outgrowth from cultured embryonic rat hippocampal neurons. J Neurosci Res 46:349-359.
29. Insel TR. 2010. Rethinking schizophrenia. Nature 468:187-193.
30. Jett DA. 2012. Chemical toxins that cause seizures. Neurotoxicology 33:1473-1475.
31. Jongen-Relo AL, Leng A, Luber M, et al. 2004. The prenatal methylazoxymethanol acetate treatment: a neurodevelopmental animal model for schizophrenia? Behav Brain Res 149:159-181.
32. Karlsson A, Lindquist C, Malmgren K, Asztely F. 2011. Altered spontaneous synaptic inhibition in an animal model of cerebral heterotopias. Brain Res 1383:54-61.
33. Kisby GE, Eizirik D, Sweatt C, Spencer PS. 1995. Reactive oxygen species produced by the cycad toxin methylazoxymethanol, a candidate etiological factor for western Pacific ALS/P-D. J Cell Biochem 21B:99.
34. Kisby GE, Ellison M, Spencer PS. 1992. Content of the neurotoxins cycasin (methylazoxymethanol β-D-glucoside) and BMAA (β-N-methylamino-L-alanine) in cycad flour prepared by Guam Chamorros. Neurology 42:1336-1340.
35. Kisby GE, Fry RC, Lasarev MR, et al. 2011. The cycad genotoxin MAM modulates brain cellular pathways involved in neurodegenerative disease and cancer in a DNA damage-linked manner. PLoS One 6:e20911.
36. Kisby GE, Kabel H, Hugon J, Spencer P. (1999) Damage and repair of nerve cell DNA in toxic stress. Drug Metab Rev 31:589-618.
37. Kisby GE, Olivas A, Park T, et al. 2009. DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair (Amst) 8:400-412.
38. Kisby GE, Olivas A, Standley M, et al. 2006. Genotoxicants target distinct molecular networks in neonatal neurons. Environ Health Perspect 114:1703-1712.
39. Kisby GE, Spencer PS. 2011. Is neurodegenerative disease a long-latency response to early-life genotoxin exposure? Int J Environ Res Public Health 8:3889-3921.
40. Kisby GE, Standley M, Lu X, et al. 2005. Molecular networks perturbed in a developmental animal model of brain injury. Neurobiol Dis 19:108-118.
41. Ko HG, Jang DJ, Son J, et al. 2009. Effect of ablated hippocampal neurogenesis on the formation and extinction of contextual fear memory. Mol Brain 2:1.
42. Kobayashi A, Matsumoto H. 1965. Studies on methylazoxymethanol, the aglycone of cycasin. Isolation, biological, and chemical properties. Arch Biochem Biophys 110:373-380.
43. Laqueur GL, Matsumoto H. 1967. Neoplasms in female Fischer rats following intraperitoneal injection of methylazoxymethanol. J Natl Cancer Inst 124:691-697.
44. Lee CY, Delaney JC, Kartalou M, et al. 2009. Recognition and processing of a new repertoire of DNA substrates by human 3-methyladenine DNA glycosylase (AAG). Biochemistry 48:1850-1861.
45. Le Pen G, Gourevitch R, Hazane F, et al. 2006. Peri-pubertal maturation after developmental disturbance: a model for psychosis onset in the rat. Neuroscience 143:395-405.
46. Lessell S, Torres JM, Kurland LT. 1962. Seizure disorders in a Guamanian village. Arch Neurol 7:37-44.
47. Lodge DJ. 2013. The MAM rodent model of schizophrenia. Curr Protoc Neurosci Chapter 9; Unit9.43.
48. Lodge DJ, Grace AA. 2009. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 204:306-312.
49. Mackowiak M, Bator E, Latusz J, et al. Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex. Eur Neuropsychopharmacol, in press. DOI: 10.1016/j.euroneuro.2013.05.013.
50. Matsumoto H, Higa HH. 1966. Studies on methylazoxymethanol, the aglycone of cycasin: methylation of nucleic acids in vitro. Biochem J 98:20C-22C.
51. Matsumoto H, Spatz M, Laqueur GL. 1972. Quantitative changes with age in the DNA content of methylazoxymethanol-induced microencephalic rat brain. J Neurochem 19:297-306.
52. Matsumoto H, Strong FM. 1963. The occurrence of methylazoxymethanol in cycas circinalis L. Arch Biochem Biophys 101:299-310.
53. +-dependent and phlorizin-inhibitable transport of glucose and cycasin in brain endothelial cells. J Neurochem 70:772-777.
54. Maysami S, Lan JQ, Minami M, Simon RP. 2008. Proliferating progenitor cells: a required cellular element for induction of ischemic tolerance in the brain. J Cereb Blood Flow Metab 28:1104-1113.
55. Merker RJ, Graham P, Cressman V, et al. 2009. Abnormal neonatal and adult gene expression patterns in the hippocampus and prefrontal cortex of offspring of rat dams exposed to MAM on embryonic day 17. Soc Neurosci Abstr 341:5.
56. Moore H, Jentsch JD, Ghajarnia M, et al. 2006. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry 60:253-264.
57. 2O. Nature 236:234-235.
58. Nagata Y, Matsumoto H. 1969. Studies on methylazoxymethanol: methylation of nucleic acids in the fetal rat brain. Proc Soc Exp Biol Med 132:383-385.
59. Osborne R, Grove A, Oh P, et al. 1994. The magical and medicinal usage of Stangeria eriopus in South Africa. J Ethnopharmacol 43:67-72.
60. Perse M, Cerar A. 2011. Morphological and molecular alterations in 1, 2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. J Biomed Biotechnol 2011:473964.
61. Potschka H. 2012. Animal models of drug-resistant epilepsy. Epileptic Disord 14:226-234.
62. Powell SB. 2010. Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Behav Neurosci 4:435-481.
63. Reed D, Labarthe D, Chen KM, Stallones R. 1987. A cohort study of amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam and Rota. Am J Epidemiol 125:92-100.
64. Sanderson TM, Cotel MC, O'Neill MJ, et al. 2012. Alterations in hippocampal excitability, synaptic transmission and synaptic plasticity in a neurodevelopmental model of schizophrenia. Neuropharmacology 62:1349-1358.
65. Schwartzkroin PA, Wenzel HJ. 2012. Are developmental dysplastic lesions epileptogenic? Epilepsia 53:35-44.
66. Shank RC, Magee PN. 1967. Similarities between the biochemical actions of cycasin and dimethylnitrosamine. Biochem J 105:521-527.
67. Shimizu T, Yasuda N, Kono I, et al. 1986. Hepatic and spinal lesions in goats chronically intoxicated with cycasin. Jpn J Vet Sci 48:1291-1295.
68. Shiraki H, Yase Y. 1975. ALS in Japan. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. New York: Elsevier. pp. 353-419.
69. Shors TJ, Miesegaes G, Beylin A, et al. 2001. Neurogenesis in the adult is involved in the formation of trace memories. Nature 410:372-376.
70. Sieber SM, Correa P, Dalgard DW, et al. 1980. Carcinogenicity and hepatotoxicity of cycasin and its aglycone methylazoxymethanol acetate in nonhuman primates. J Natl Cancer Inst 65:177-189.
71. 6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Proc Natl Acad Sci USA 93:6941-6946.
72. Spencer PS. 1990. Are neurotoxins driving us crazy? Planetary observations of neurodegenerative diseases of old age. In: Russell RW, Flattau PE, Pope AM, editors. Behavioral measures in neurotoxicity. Washington, DC: National Academy Press. p. 11.
73. Spencer PS, Fry RC, Palmer VS, Kisby GE. 2012. Western Pacific ALS-PDC: a prototypical neurodegenerative disorder linked to DNA damage and aberrant proteogenesis? Front Neurol 3:180.
74. Spencer PS, Kisby GE. 1992. Slow toxins and western Pacific amyotrophic lateral sclerosis. In: Smith RA, editor. Handbook of amyotrophic lateral sclerosis. New York: Marcel Dekker pp. 575-585.
75. Spencer PS, Kisby GE, Ludolph AC. 1991. Slow toxins, biologic markers, and long-latency neurodegenerative disease in the western Pacific region. Neurology 41:62-66.
76. Spencer PS, Ohta M, Palmer V. 1987. Cycad use and motor neuron disease in Kii peninsula of Japan. Lancet 2:1462-1463.
77. Sullivan-Jones P, Gouch AB, Holson RR. 1994. Postnatal methylazoxymethanol: sensitive periods and regional selectivity of effects. Neurotoxicol Teratol 16:631-637.
78. Tabata RC, Wilson JM, Ly P, et al. 2008. Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype. Neuromolecular Med 10:24-39.
79. Tate ME, Delaere IM, Jones GP, Tierkink ERT. 1995. Crystal and molecular structure of (Z)-β-O-D-glucopyranosyloxy-NNO-azoxymethane. Aust J Chem 48:1059.
80. Ueda S, Yoshimoto K, Kadowaki T, et al. 2010. Improved learning in microencephalic rats. Congenit Anom (Kyoto) 50:58-63.
81. Wallace CS, Reitzenstein J, Withers GS. 2003. Diminished experience-dependent neuroanatomical plasticity: evidence for an improved biomarker of subtle neurotoxic damage to the developing rat brain. Environ Health Perspect 111:1294-1298.
82. Whiting M. 1964. Food practices in ALS foci in Japan, the Marianas, and New Guinea. Fed Proc 23:1343-1345.
83. Whiting M. 1988. Toxicity of cycads: implications for neurodegenerative diseases and cancer. Transcripts of Four Cycad Conferences; Third World Medical Research Foundation, NY.
84. Whiting MG. 1963. Toxicity of cycads. Econ Bot 17:271-302.
85. Wilson JM, Khabazian I, Wong MC, et al. 2002. Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. Neuromol Med 1:207-221.
86. Woo YT, Lai DY, Arcos JC, Argus MF. 1988. Natural, metal, fiber and macromolecular carcinogens (Section 5.3.2.2. Cycasin and related compounds). In: Chemical induction of cancer. Structural basis and biological mechanisms, San Diego: Academic Press. p. 178.
87. Yagi F, Tadera K. 1987. Azoxyglycoside contents in seeds of several cycad species and various parts of Japanese cycad. Agric Biol Chem 51:1719-1721.
88. Yase Y. 1972. The pathogenesis of amyotrophic lateral sclerosis. Lancet 2:292-296.
89. Zeller WJ. 1992. Neurotrophic carcinogenesis. In: Herken H, Hucho F, editors. Selective neurotoxicity. Vol. 102. Berlin: Springer-Verlag. pp. 193-224.
90. Zhang ZX, Anderson DW, Mantel N, Román GC. 1996. Motor neuron disease on Guam: geographic and familial occurrence, 1956-85. Acta Neurol Scand 94:51-59.